ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1800

A Declining Trend in Frequency of Secondary Amyloidosis in Behçet’s Syndrome

Guzin Karatemiz1, Sinem Nihal Esatoglu1, Yesim Ozguler1, Sebahattin Yurdakul1, Vedat Hamuryudan1, Melike Melikoglu1, Izzet Fresko1, Emire Seyahi1, Serdal Ugurlu1, Huri Ozdogan1, Hasan Yazici2 and Gulen Hatemi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul Academic Hospital, Istanbul, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and amyloidosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: A decline in the frequency of AA amyloidosis secondary to RA and infectious diseases has been reported. This is probably due to more effective treatment strategies. We had previously reported that although amyloidosis occurs in less than 0.5% of BS pts. It is one of the leading causes of death (1-3). We aimed to determine the change in the frequency of AA amyloidosis over years in BS pts in addition to elaborating on clinical characteristics and outcome.

Methods: We performed a chart review to identify all pts with amyloidosis in our BS center since1976. We noted demographic characteristics, BS manifestations, age at BS and AA amyloidosis diagnosis, treatment modalities of these pts. Our endpoints were death and end stage renal disease (ESRD) requiring renal replacement therapy. The prevalence of AA amyloidosis was calculated separately for 2 periods (pts registered between 1976-2000 and 2000-2017)

Results: Among our 9410 BS pts, 27 (0.29%) had amyloidosis. We identified 24 pts with amyloidosis among the 3820 pts in the earlier cohort and 3 additional amyloidosis among the 5590 pts in the recent cohort. The frequency of AA amyloidosis had declined from 0.62% to 0.054% in the recent cohort. M/F ratio was 22/5 and mean age at BS diagnosis was 29.5±7.4 yrs. Twenty-two (82%) of the pts with AA amyloidosis had major organ involvement (vascular inv. in 15, eye inv.in 13 and neurologic inv.in 2). AA amyloidosis was diagnosed after a mean duration of 9.8±6.7 yrs and was confirmed with renal biopsy in 14 pts and rectal biopsy in 13. Eight pts had non-nephrotic range proteinuria at amyloidosis diagnosis. After amyloidosis diagnosis, 24 pts continued their previous immunosuppressives and colchicine. Two of these 24 were on anti-TNFs at amyloidosis diagnosis. Biologics were initiated in 3 pts who were most recently diagnosed to have amyloidosis, anti-TNFs in 2 and tocilizumab in 1. Fourteen (52%) pts had died after a median follow-up of 3 (IQR:1-8.75) yrs, 3 were lost to follow-up just after amyloidosis diagnosis and 10 (37%) are still alive after a median follow up of 16 (IQR:10-23) yrs. The reasons for death were infections in 5, related to ESRD in 5, subarachnoid hemorrhage, gastric adenocarcinoma, liver cirrhosis probably associated with amyloidosis and iatrogenic bowel perforation in 1 pts each. 10 (71%) of these 14 pts had developed ESRD before their deaths. Overall, 15/27 pts developed ESRD after a median follow-up of 3.5 (IQR:1.25-6.5) yrs after amyloidosis diagnosis. 5 of them had renal transplantation, all but 1 are still alive after 3, 4, 6, and 12 yrs. The last one died 11 years after transplantation due to subarachnoid hemorrhage as explained above.

Conclusion:

AA amyloidosis appears to be a rare, but fatal complication of BS. Around 50% of pts died after a median follow-up of 3 yrs after amyloidosis. This study showed a decreasing trend of amyloidosis due to BS similar to that observed in other inflammatory and infectious causes. The shorter follow-up duration may be contributing for the lower prevalence of amyloidosis in the recent cohort.

References

1)Yurdakul S,Arthritis Rheum.1990 2)Melikoğlu M,Rheumatology (Oxford).2001 3)Kural-Seyahi E,Medicine (Baltimore).2003


Disclosure: G. Karatemiz, None; S. N. Esatoglu, None; Y. Ozguler, None; S. Yurdakul, None; V. Hamuryudan, None; M. Melikoglu, None; I. Fresko, None; E. Seyahi, None; S. Ugurlu, None; H. Ozdogan, None; H. Yazici, None; G. Hatemi, None.

To cite this abstract in AMA style:

Karatemiz G, Esatoglu SN, Ozguler Y, Yurdakul S, Hamuryudan V, Melikoglu M, Fresko I, Seyahi E, Ugurlu S, Ozdogan H, Yazici H, Hatemi G. A Declining Trend in Frequency of Secondary Amyloidosis in Behçet’s Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-declining-trend-in-frequency-of-secondary-amyloidosis-in-behcets-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-declining-trend-in-frequency-of-secondary-amyloidosis-in-behcets-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology